About the ESP
Throughout the project, we will engage in frequent and in-depth dialogue with various stakeholders, also outside of the Trials@Home consortium.
This allows us to incorporate the views and knowledge of such stakeholders including patients, (clinical) researchers, healthcare providers, regulators, payers, Health Technology Assessment (HTA) groups, and ethics bodies. Representatives of these stakeholder groups will be invited to serve on the Trials@Home External Stakeholder Platform (ESP).
The (members of) the ESP will be consulted by the different work package teams several times per year to inform and provide expert feedback on key elements of the activities to ensure relevance, feasibility, attractiveness and practicability of project deliverables and create a sense of ‘co-ownership’ of the Trials@Home recommendations and findings, further promoting their future adoption. Concrete directions and guidelines will ensure that results have an immediate impact on drug development.